Literature DB >> 11036954

The clinical pharmacology of alkylating agents in high-dose chemotherapy.

A D Huitema1, K D Smits, R A Mathôt, J H Schellens, S Rodenhuis, J H Beijnen.   

Abstract

Alkylating agents are widely used in high-dose chemotherapy regimens in combination with hematological support. Knowledge about the pharmacokinetics and pharmacodynamics of these agents administered in high doses is critical for the safe and efficient use of these regimens. The aim of this review is to summarize the clinical pharmacology of the alkylating agents (including the platinum compounds) in high-dose chemotherapy. Differences between conventional and high doses will be discussed.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11036954     DOI： 10.1097/00001813-200008000-00002

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN： 0959-4973            Impact factor:   2.248


  10 in total

Review 1.  Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors:  Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

2.  Chemotherapy agents: a primer for the interventional radiologist.

Authors:  Frank Mihlon; Charles E Ray; Wells Messersmith
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

3.  Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Authors:  Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

4.  Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.

Authors:  Priya P Gor; H Irene Su; Robert J Gray; Phyllis A Gimotty; Michelle Horn; Richard Aplenc; William P Vaughan; Martin S Tallman; Timothy R Rebbeck; Angela DeMichele
Journal:  Breast Cancer Res       Date:  2010-05-10       Impact factor: 6.466

5.  Regulation of therapeutic resistance in cancers by receptor tyrosine kinases.

Authors:  Mei-Kuang Chen; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2016-03-15       Impact factor: 6.166

Review 6.  A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.

Authors:  Gabriel W Loh; Lillian S L Ting; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients.

Authors:  Gaurav Agarwal; Sonam Tulsyan; Punita Lal; Balraj Mittal
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

8.  Dioscorea bulbifera polysaccharide and cyclophosphamide combination enhances anti-cervical cancer effect and attenuates immunosuppression and oxidative stress in mice.

Authors:  Hongxia Cui; Ting Li; Liping Wang; Yan Su; Cory J Xian
Journal:  Sci Rep       Date:  2016-01-12       Impact factor: 4.379

9.  High-dose thiotepa-related neurotoxicity and the role of tramadol in children.

Authors:  Christophe Maritaz; Francois Lemare; Agnes Laplanche; Sylvie Demirdjian; Dominique Valteau-Couanet; Christelle Dufour
Journal:  BMC Cancer       Date:  2018-02-13       Impact factor: 4.430

Review 10.  Antineoplastics Encapsulated in Nanostructured Lipid Carriers.

Authors:  Gustavo Henrique Rodrigues da Silva; Ludmilla David de Moura; Fabíola Vieira de Carvalho; Gabriela Geronimo; Talita Cesarim Mendonça; Fernando Freitas de Lima; Eneida de Paula
Journal:  Molecules       Date:  2021-11-17       Impact factor: 4.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.